KDR and neoplasm: Initiating the treatment of tumour bearing WT mice at day 10 with the VEGFR2 inhibitor (Ki8751; 20 mg/kg/day i.p) significantly (P < 0.01) suppressed tumour development, compared to vehicle treatment, indicating that VEGFR2 drives tumour development in this animal model (Figure 2A).